Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation.

Oncology research and treatment - 1 Jan 2023

Costa Bruno Almeida, Tallón de Lara Paulino, Park Wungki, Keane Fergus, Harding James J, Khalil Danny N

Abstract excerpt

INTRODUCTION: Despite major advances in surveillance and management, advanced cholangiocarcinoma (CCA) still carries a dismal prognosis. In recent years, several actionable genomic alterations in pancreatobiliary malignancies have been identified. For instance, homologous recombination deficiency (HRD) has been considered a predictive biomarker of clinical response to platinum and poly (ADP-ribose) polymerase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Duct Neoplasms
Share to Bile Ducts, Intrahepatic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Germ Cells

Share to Mutation

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Source

Identifiers

PMID: 36882017
DOI: 10.1159/000529919

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation.PMID 36882017Read ↗

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?Semantic proximity Read ↗

Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.Semantic proximity Read ↗

Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studiesSemantic proximity Read ↗

Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world studySemantic proximity Read ↗

An evaluation of olaparib for the treatment of pancreatic cancer.Semantic proximity Read ↗

Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect?Semantic proximity Read ↗

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation.Semantic proximity Read ↗

Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.Semantic proximity Read ↗

PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution ExperienceSemantic proximity Read ↗

Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial.Semantic proximity Read ↗

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II TrialSemantic proximity Read ↗

Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.